Experimental cell therapy takes on Drug-Resistant melanoma
NCT ID NCT06708455
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests a new cell therapy called RAPA-201 for people with advanced melanoma that has stopped responding to PD-(L)1 inhibitors. The therapy uses a patient's own immune cells, modified to resist the drug rapamycin, and is given along with chemotherapy. The study aims to see if this combination can shrink tumors and improve outcomes in 65 participants with stage IIIc or IV melanoma.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RAPA-201 (a type of immune cell therapy made from the patient's own cells, designed to resist the drug rapamycin) plus chemotherapy (carboplatin and paclitaxel)
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced melanoma that no longer responds to standard immunotherapy.
- What could go wrong
- This is an early Phase 2 trial with only 65 people, so results may not apply to everyone. The treatment involves strong chemotherapy and cell therapy, which can cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can two immune boosters beat advanced melanoma?
- Drug duo takes on rare head and neck tumors
- Experimental cancer therapy targets tough tumors with radioactive precision
- Keytruda immune response trial aims to unlock cancer clues
- Experimental combo aims to supercharge cancer immunotherapy
- AI-Designed mRNA vaccine takes on advanced tumors in first human test